TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
Frequently asked questions
What sector does TME Pharma N.V. (ALTME) operate in?
TME Pharma N.V. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TME Pharma N.V. (ALTME) current stock price?
As of the latest data, TME Pharma N.V. stock price is €0.06, with a previous close of €0.06.
What is TME Pharma N.V. (ALTME) current market capitalization?
TME Pharma N.V. market cap is approximately 5.80 million.
What is TME Pharma N.V. (ALTME) Earnings Per Share (EPS)?
The trailing EPS is -€0.03, and the forward EPS is -€0.87.
Does TME Pharma N.V. (ALTME) pay dividends?
No. TME Pharma N.V. does not pay a dividend.
What is TME Pharma N.V. (ALTME) beta (volatility) score?
TME Pharma N.V. has a beta of 0.635, indicating lower volatility than the overall market.
